The Affordable Care Act was former President Barack Obama’s signature healthcare reform. It is known as Obamacare, but only informally. President Donald Trump wasn’t so subtle in claiming credit for his effort, boldly branded as TrumpRx.
Go to the website TrumpRx.gov, and it will tell you three things near the top of the page: This is the place to find the “world’s lowest prices on prescription drugs,” “We’re just getting started,” and you can “get updates as new medications are added” by creating an account.
The site launched Feb. 5.
“This is a very big deal. People are going to save a lot of money and be healthy,” Trump said in a press conference that day. But how big a deal is it, in terms of the overall healthcare industry in America
The Washington Examiner asked several experts in healthcare policy and related fields for their assessment. Several of them offered to help Sherpa curious parties through this new pharma care offering.
The TrumpRx website lists prices for a “limited number of brand-name medications and directs users to other sites where they can purchase them,” explained Chelsea Boyd, a research fellow for the R Street Institute. “Those prices are all based on a person paying for the medication without insurance.”
TrumpRx is similar to other long-standing pharma pricing websites, such as GoodRx, Boyd said. And it’s probably a good idea to shop around by looking at several different sites.
“Since some of the drugs have generic versions available, TrumpRx prices may not be the most affordable option in all cases,” she explained. “People with insurance should also make sure they understand how paying for prescriptions directly may affect progress towards meeting deductibles and out-of-pocket maximums.”
As for the overall impact of TrumpRx, Boyd thought that it “might benefit a small group of Americans, like people who are uninsured or choose to purchase name-brand over generics.”
Her assessment was on the low end, but all the experts consulted agreed that this will likely be a reform with real but limited impact when it comes to bringing down overall healthcare costs.
Rx growing pains
Edmund “Ed” Haislmaier is a research fellow in health and welfare policy for the Heritage Foundation. He stressed that TrumpRx is still in its toddlerhood.
“It’s been developed and launched, and now you have the buildout phase,” Haislmaier said.
There are 40-plus drugs priced currently, including the popular weight-loss drugs Wegovy and Ozempic. As the offerings on the TrumpRx site multiply, its impact is likely to grow as well.
Yet Haislmaier pointed out that even if every single FDA-approved drug were listed at a reduced price, that still wouldn’t affect the lion’s share of healthcare spending.
“That’s 10% of your total healthcare spending, all the drugs,” he said.
Haislmaier views TrumpRx as more than a gimmick.
“It’s a positive incremental step toward the much larger goal,” he said, and that goal needs to be “price transparency” on all healthcare spending.
TrumpRx could also end up being a test case of how far a president can go with a reform without congressional authorization. That’s because it is grounded not in legislation but in an executive order signed by Trump last year.
“If someone is on a Medicare Part D Plan,” and they use TrumpRx, Haislmaier set up the question, “Does that count toward their deductible?” A private insurer could decide to count that spending toward a deductible unilaterally, he said, but Congress would likely have to “adjust the statute” to allow it.
Haislmaier isn’t sure about the prospects for such a change in the current Congress, noting an “entrenched animosity” by Democrats to most of the things Trump proposes. Still, he said a deal “is theoretically possible” and noted that parts of the Democratic coalition might ultimately favor this reform. Many unions, for instance, which have their own healthcare plans, might welcome lower drug prices.
Premiums and taxes
Gabrielle “Elle” Minarik is a program manager at the Paragon Health Institute, which specializes in health care reform. She had the most positive things to say about TrumpRx out of all the experts consulted.
“Overall, TrumpRx is a great step in policy” and is a “really important step toward a direct-to-consumer model” of healthcare, she told the Washington Examiner. She argued that for it to have as much impact as possible, it “needs to be integrated with commercial insurance,” and Congress should follow the administration’s lead.
Minarik warned that, absent serious cost-cutting reforms, of which TrumpRx is but a small part, healthcare is only going to become more expensive. “Our healthcare system has a cost containment problem,” caused by “oversubsidizing,” she said. That is to say that the way the current system is set up distorts the healthcare economy in ways that don’t allow for much price competition, with ever-rising insurance premiums as the result.
Pete Sepp, president of the National Taxpayers Union, called direct-to-consumer purchasing a “helpful competitive development in the prescription drug market” and noted that TrumpRx is only the latest in that space, with other platforms, including “Cost Plus Drugs, Amazon Pharmacy, and GoodRx [already] offering various brand and generic discounts.” Unlike these other platforms, “taxpayers helped to build TrumpRx and will presumably chip in to keep the portal running,” he said.
Sepp did see some potential government spending-side savings from TrumpRx.
“The Federal Employees Health Benefit Program, more than 70% of whose premiums are covered by taxpayers, is integrated with TrumpRx,” he pointed out as one example. “So, for FEHBP participants in a spotty coverage situation with particular drugs, TrumpRx might save them some money, and as a result, there would be less pressure on taxpayers to chip in for more generous insurance.”
The NTU president worries that pharmaceutical price controls, with which the Trump administration has experimented, could threaten the new initiative’s success.
“As long as mandatory price controls are on the table, TrumpRX and other direct-to-consumer platforms face massive headwinds in delivering sustainable savings across broad classes of drugs,” he warned.
Rx of the union
So far, Democratic protests to TrumpRx have been understated. A few members of the House and Senate sent out a letter of protest to Health and Human Services Secretary Robert F. Kennedy, Jr. in October 2025 and an accompanying press release that complained about the Trump administration’s “lack of transparency” in evaluating drug prices.
“We are deeply concerned that [TrumpRx] will be yet another Administration action that enriches companies and industries with close ties to President Trump while doing nothing to reduce the excessively high costs of prescription drugs for Americans,” Sen. Ron Wyden (D-OR) and Reps. Richard Neal (D-MA) and Frank Pallone Jr. (D-NJ) wrote at the time.
That concern has not become more urgent, even after TrumpRx’s release.
“I took prescription drugs, a very big part of healthcare, from the highest price in the entire world to the lowest,” Trump bragged in his Feb. 24 State of the Union address and pointed to one success story in the crowd.
IRAN NAMES MOJTABA KHAMENEI, SON OF AYATOLLAH ALI KHAMENEI, AS THE NEW SUPREME LEADER
Trump said Catherine Rayner and her husband had been trying to have children for years. One IVF drug had cost the couple more than $4,000 to purchase, which she was able to find on TrumpRx for less than $500. “Catherine, we are all praying for you, and you’re going to be a great mom,” Trump said, to some applause.
Gov. Abigail Spanberger (D-VA), six weeks into the job, was charged with giving the Democratic response to Trump’s address. She responded to many of the president’s claims in a speech delivered from Colonial Williamsburg, a living history museum with restored 18th-century buildings. Yet she did not mention TrumpRx, even in passing.
Jeremy Lott (@jeremylottdiary) is the author of several books, most recently The Three Feral Pigs and the Vegan Wolf.
